Unknown PHASE2 INTERVENTIONAL 1-arm NCT01210053

Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

This Phase II Trial is Studying Sunitinib to See How Well it Works When Given as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer Which is Previously Treated With Combination Chemotherapy.

Sponsor: Third Military Medical University

Conditions Non-small Cell Lung Cancer

Interventions malate Given orally

Updated 5 times since 2017 Last updated: Sep 27, 2010 Started: Sep 30, 2010 Primary completion: Nov 30, 2011 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-small Cell Lung Cancer and is currently ongoing. Third Military Medical University leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Feb 2017 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Third Military Medical University

Data source: Third Military Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chongqing, China